(Albany, US) DelveInsight launched a new report on Cytokine Release Syndrome Market Insights, Epidemiology and Market Forecast-2030
DelveInsight’s “Cytokine Release Syndrome – Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Cytokine Release Syndrome, historical and forecasted epidemiology as well as the Cytokine Release Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the report:
1. A total number of patients who develop Cytokine Release Syndrome following CART therapies in the 7MM was 31 in 2017.
2. A total number of Hematologic patients receiving CART-therapies in the 7MM was 41 in 2017.
3. Cytokine Release Syndrome cases in the United States was 31 in 2017.
Key benefits of the report
1. Cytokine Release Syndrome market report covers a descriptive overview and comprehensive insight of the Cytokine Release Syndrome epidemiology and Cytokine Release Syndrome market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Cytokine Release Syndrome market report provides insights into the current and emerging therapies.
3. Cytokine Release Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Cytokine Release Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cytokine Release Syndrome market.
Request for Free Sample Pages : https://www.delveinsight.com/sample-request/cytokine-release-syndrome-market
“Cytokine Release Syndrome market size in the 7MM was USD 0.16 million in 2017.”
Cytokine Release Syndrome is among the most frequent serious adverse events and represents a significant cause of morbidity following T-cell-engaging immunotherapy. The mechanisms of Cytokine Release Syndrome and the clinical use of corticosteroids and IL-6 blockade have already improved the management of Cytokine Release Syndrome patients.
Currently, there are many other IL-6-targeting monoclonal antibodies in late-stage clinical development, which could also potentially be used for Cytokine Release Syndrome treatment.
With the growing use of T-cell engaging therapies, there is an urgent need for clinical trials that improve the evidence base for the Cytokine Release Syndrome treatment. Our current management strategies for the disease are predominantly based on biologic reasoning, expert opinion, and retrospective analyses.
The recent approval of CAR T-cell therapies and their increase in the treatment of various oncology indications is increasing the Cytokine Release Syndrome incidence. The rise in the Cytokine Release Syndrome incidence stimulates the research and development of the drug, as it is likely to provide an appropriate environment for newer products to be profitable. Companies across the globe have shifted their focus toward the treatment of Cytokine Release Syndrome. The increase in the incidence will potentiate the Cytokine Release Syndrome treatment market.
The launch of the emerging therapies is expected to significantly impact Cytokine Release Syndrome treatment scenario in the upcoming years:-
Drugs covered:
1. Canakinumab (Ilaris)
2. Itacitinib
3. Cytosorb
4. Defitelio (Defibrotide)
5. Anakinra
And many others
The key players in Cytokine Release Syndrome market are:
1. Novartis Pharmaceuticals
2. Incyte Corporation
3. CytoSorbents
4. Jazz pharmaceuticals
5. Swedish Orphan Biovitrum (Sobi)
Table of contents
1Key Insights 2 Executive Summary of Cytokine Release Syndrome 3 Cytokine Release Syndrome Market Overview at a Glance 4 Disease Background and Overview Cytokine Release Syndrome 5 Case Reports 6 Cytokine Release Syndrome Epidemiology and Patient Population 7 United States Epidemiology 8 EU5 Epidemiology 8.1 Assumptions and Rationale 8.2 Germany Epidemiology 8.3 France Epidemiology 8.4 Italy Epidemiology 8.5 Spain Epidemiology 8.6 United Kingdom Epidemiology 9 Japan Epidemiology 10 Current Cytokine Release Syndrome Treatment and Medical Practices 11 Unmet needs 12 Cytokine Release Syndrome Marketed Drugs 12.1 Actemra/RoActemra (tocilizumab): Genentech 13 Cytokine Release Syndrome Emerging Drugs 13.1 Key Cross Competition 13.2 Canakinumab (Ilaris): Novartis Pharmaceuticals 13.3 Itacitinib: Incyte Corporation 13.4 Cytosorb: CytoSorbents 13.5 Defitelio (Defibrotide): Jazz pharmaceuticals 13.6 Anakinra: Swedish Orphan Biovitrum (Sobi) 14 Cytokine Release Syndrome 7MM Market Analysis 15 Conjoint Analysis 16 United States 16.1 United States Market Outlook 16.2 United States Market Size 17 EU-5 Countries: Market Outlook 17.1 Germany Market Size 17.2 France Market Size 17.3 Italy Market Size 17.4 Spain Market Size 17.5 United Kingdom Market Size 18 Japan Market Outlook 19 Cytokine Release Syndrome Market Drivers 20 Cytokine Release Syndrome Market Barriers 21 SWOT Analysis 22 Reimbursement and market access 23 Appendix 24 DelveInsight Capabilities 25 Disclaimer
Request for Detailed TOC: https://www.delveinsight.com/sample-request/cytokine-release-syndrome-market
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/cytokine-release-syndrome-market